Unichem Laboratories share gains on receiving USFDA approval for hypertension tablets

Unichem Laboratories Ltd, an international, integrated, speciality pharmaceutical company, announced on Tuesday that it has received approval from United States Food & Drug Administration (USFDA) to market its hypertension tablets.

The company received abbreviated new drug application (ANDA) approval for its Atenolol and Chlorthalidone tablets, USP 50 mg/25 mg and 100 mg/25 mg from USFDA. It is a generic version of Tenoretic Tablets of Alvogen Malta Operations Limited. The drug is used in the treatment of hypertension, to lower blood pressure. The tablets are said to be commercialised from the company’s Ghaziabad plant.

The company manufactures and markets a large basket of pharmaceutical formulations as branded generics in various markets across the world. It earns approximately 66 per cent of its revenue from the USA market, 3 per cent from the domestic market, and 31 per cent from other markets. Product-wise, its formulations contribute 90 per cent to the revenue while bulk drug & chemicals contribute 10 per cent.

At 1.52 pm today, its share was trading 1.53 per cent higher at Rs 259.40. It recorded an intraday high of Rs 267.65 and an intraday low of Rs 259.40 on BSE.